Based on the recent earnings conference call transcripts, the following key financial metrics should be highlighted in the summary report:

1. Organic Sales Growth: The company achieved a 6.7% organic sales growth in the second quarter, with strong momentum seen across key divisions such as Orthopaedics, MedSurg, and Neurotechnology segments. International organic sales growth was also strong at 5.5%, driven by performances in Europe and Australia.

2. Earnings Per Diluted Share (EPS): The adjusted quarterly EPS of $1.53 increased by 10.1% from the prior year, reflecting strong sales growth, accretive acquisitions, operating expense control, and the benefit from the change in accounting guidance for tax benefits from certain stock compensation expenses.

3. Segment Performance: Orthopaedics delivered constant currency growth of 6.5% and organic growth of 6.2%, with strong demand for 3D-printed products and knee and trauma extremities products. MedSurg achieved constant currency growth of 6.8% and organic gains of 6.7%, with strong demand for instruments and endoscopy products.

4. Gross Margin: The adjusted gross margin of 66.3% was up 10 basis points from the prior-year quarter, reflecting a favorable mix, offset by price and foreign exchange related to certain businesses.

5. Operating Margin: The adjusted operating margin was 25% of sales, representing a 20 basis point improvement from the prior-year quarter. The company remains confident in its ability to deliver a full-year commitment of 30 to 50 basis point improvement in operating margin.

6. Effective Tax Rate: The second quarter adjusted effective tax rate of 16.3% reflects a larger-than-anticipated benefit related to the adoption of changes in accounting for stock compensation expenses. The anticipated effective tax rate for the second half of the year ranges from 16% to 17%.

7. Balance Sheet and Cash Flow: The company maintains a strong balance sheet with $3.7 billion of cash and marketable securities and total debt of $7.4 billion. Cash from operations was approximately $801 million.

Based on the guidance provided, the company anticipates annual organic sales growth to be in the range of 6.5% to 7% for 2017 and expects adjusted net earnings per diluted share to be in the range of $6.45 to $6.55, excluding any anticipated dilution related to planned acquisitions.

Overall, the company's financial performance in the second quarter and outlook for the full year demonstrate strong sales growth, margin improvement, and effective tax management. Additionally, the company is making strategic investments in its operating expenses and growth platforms to drive future operational savings and product growth.